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Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression
indicates poor prognosis in pancreatobiliary differentiated tumours
Aims: To examine how accurately immunohisto-
chemical markers discriminate between pancreato-
biliary and intestinal-type adenocarcinomas in the
pancreatic head and to explore the prognostic impor-
tance of these markers among each of these histological
types.
Methods and results: Histopathological features of 114
consecutively resected adenocarcinomas of pancreato-
biliary (n = 67) and intestinal (n = 47) type of differ-
entiation were recorded according to a standardized
protocol. Immunohistochemistry for cytokeratin (CK)
7, CK20, MUC1, MUC2, MUC4 and CDX2 was
performed on tissue microarrays. Classiﬁcation of the
adenocarcinomas based on immunohistochemistry was
compared with the morphological evaluation of histo-
logical type. Presence of CK7 and MUC4, and absence
of CDX2, were independent predictors of pancreato-
biliary versus intestinal type. Using these markers to
optimize immunohistochemical classiﬁcation, agree-
ment between immunohistochemical and morpholog-
ical classiﬁcation was only moderate (j = 0.53). In
pancreatobiliary differentiated tumours, MUC1 and ⁄ or
MUC4 expression was an independent prognostic factor
(hazard ratio 2.02, 95% conﬁdence interval 1.02,
3.98) when adjusting for nodal involvement, vessel
involvement and tumour size. In intestinally differen-
tiated tumours, none of the markers was signiﬁcantly
associated with prognosis.
Conclusions: Agreement between immunohistochemi-
cal and morphological classiﬁcation of pancreatic head
adenocarcinomas is moderate. In pancreatobiliary
adenocarcinomas, MUC1 and ⁄ or MUC4 expression
indicates a particularly poor prognosis.
Keywords: histological differentiation, immunohistochemical markers, intestinal histological type, pancreatic head
adenocarcinoma, pancreatobiliary histological type
Abbreviations: CI, conﬁdence interval; CK, cytokeratin
Introduction
Resectable adenocarcinomas in the pancreatic head
may originate from pancreatic, ampullary, distal bile
duct or duodenal tissue.
1,2 The histological appear-
ance of these adenocarcinomas, typically either pan-
creatobiliary or intestinal, often resembles the site of
origin.
3 However, ampullary,
4,5 distal bile duct
6,7 and
pancreatic tumours
8,9 may have features of both
phenotypes, and duodenal adenocarcinomas may be
impossible to discriminate from intestinal type ampul-
lary adenocarcinomas.
4 In a previous report,
10
we found that the histological type of differenti-
ation, pancreatobiliary or intestinal, was a better
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site of tumour origin, which is often difﬁcult to
determine.
4,11–16
In addition to standard histopathological exam-
ination of the resected pancreatoduodenectomy
specimens, immunohistochemical examination with
antibodies directed against differentiation markers
may be applied to discriminate between tumours
of pancreatobiliary and intestinal-type differentia-
tion.
6,8,9,17–26 No single marker has so far been found
to distinguish reliably between the two histological
types and several differentiation markers are often used
in combination.
6,22–26 The differentiation markers
most often used are cytokeratin (CK) 7 and CK20,
and the mucin proteins MUC1 and MUC2. More
recently, expression of the CDX2 homeodomain pro-
tein, important for intestinal differentiation in normal
gastrointestinal tissue,
20,27 has been shown to be
associated with intestinal-type differentiation and with
improved prognosis in pancreatic head adenocar-
cinomas.
6,8,9,19,22,25,26,28,29 The mucin protein MUC4
has been found to be aberrantly expressed in pancre-
atic adenocarcinoma
21,30–32 and in extrahepatic
bile duct carcinoma,
33 but less frequently expressed
in the normal epithelium of the duodenum and
ampulla.
34,35
The aim of the present study was to compare
immunohistochemical markers with the morphological
classiﬁcation of the histological type of differentiation
and to evaluate their prognostic importance in a cohort
of resected pancreatic head adenocarcinomas from all
four anatomical origins.
Methods
patients
Permission for the study was obtained from the
National Committee for Research Ethics. The study
comprised all patients (n = 114) with primary pan-
creatic head adenocarcinoma of pancreatobiliary
(n = 67) or intestinal (n = 47) histological type who
underwent a pancreaticoduodenectomy with curative
intent (R0 and R1 resections) during 1998–2004 at
Rikshospitalet University Hospital. Most tumours orig-
inated in the pancreas (n = 40) or the ampulla of
Vater (n = 41). Less than one-third originated in the
distal bile duct (n = 17) or the duodenum (n = 16).
Perioperative death (in-hospital death or death within
30 days of operation; n = 4) was included in the
association analysis, but excluded from survival anal-
ysis. Analysis including perioperative death gave very
similar results. No patients were lost to follow-up.
Details of the patient cohort have been previously
published.
11
histopathological assessment of specimens
Histological type of differentiation, tumour origin, pT
stage, maximum tumour diameter, resection status,
nodal involvement, perineural inﬁltration, vascular
involvement and degree of differentiation were
prospectively registered according to a standardized
protocol for histopathological examination, and
retrospectively re-evaluated by an experienced patho-
logist, as previously described.
11 The histological type
of differentiation was classiﬁed according to criteria
ﬁrst suggested by Kimura et al.,
5 later revised by
Albores-Saavedra et al.
4 Cases with mixed type
differentiation were classiﬁed according to the dom-
inant pattern.
5,10 All tumours were assigned to one
of these two histological types of differentiation.
Details of the classiﬁcation have been previously
published.
10
immunohistochemistry
Parafﬁn-embedded tissue specimens were used for
construction of tissue microarrays, using a Manual
Tissue Arrayer MTA-1 (Beecher Instruments, Inc.,
Sun Prairie, WI, USA). The arrays contained two to
four 1.0-mm cores from each tumour. Blocks were
serially sectioned at 4 lm thickness, put on slides and
stored. The sections were deparafﬁnized and pretreated
before incubation with mouse monoclonal antibodies
directed against CK7, CK20, MUC1, MUC2, MUC4
and CDX2 (Table 1). The mucins MUC1, MUC2 and
MUC4 are heavily glycosylated and changes in tissue
glycosylation can modify the reactivity to the anti-
bodies without changes in the MUC gene product at
the protein level. The speciﬁcity of the antibodies used
in the present study to detect MUC1 (clone Ma695
36)
and MUC2 (clone Ccp58
37) was, according to the
manufacturer: MUC1, carbohydrate epitope of the
human MUC1 glycoprotein; MUC2, human MUC2
glycoprotein; however, no epitope mapping studies
have been published for these antibodies. The MUC4
antibody used in the present study (clone 1G8
38)
has been shown to react with human MUC4b and
recognizes an epitope on the polypeptide chain rather
than a carbohydrate epitope.
38 All immunohistochem-
istry was performed with a Ventana Nexus Auto-
stainer using a Ventana iVIEW Diaminobenzidene
Detection kit, according to the manufacturer’s proto-
col (Ventana Medical Systems Inc., Tucson, AZ,
USA). The sections were counterstained using
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control tissues were included in the tissue microarray
blocks.
Representative tissue was obtained for all except one
tumour for CK7, MUC4 and CDX2, and for all except
three tumours for CK20 and MUC1. For CDX2, only
nuclear immunoreactivity was considered and the
percentage of positive nuclei was registered on a
continuous scale. For the remaining markers, cyto-
plasmic or membranous reactivity was classiﬁed as 0
(no reactivity), 1 (reactivity in <10% of tumour cells),
2 (reactivity in >10% but <40% of tumour cells), and 3
(reactivity in >40% of tumour cells). Intensity of
immunoreactivity was also registered, but not used
for scoring.
The level of expression representing a positive
sample was deﬁned prior to statistical analysis.
Tumours were classiﬁed as CDX2+ if nuclear reac-
tivity was seen in any tumour cell in the sample. For
all the other markers, tumours were classiﬁed as
positive if there was cytoplasmic reactivity of ‡10%
of the tumour cells. Histograms (for nuclear CDX2
reactivity) and bar graphs (for the semiquantitatively
scored markers), comparing the level of marker
expression with the histological type for each
tumour, were examined to verify that the predeﬁned
cut-off values were relevant (data not shown). For
the survival analysis, the markers were additionally
Table 1. Primary antibodies used for immunohistochemistry
Antigen
Antibody
clone Manufacturer Dilution HIER
CK7 OV-TL 12 ⁄ 30 Dako* 1:50 Tris–EDTA
CK20 Ks20.8 Dako* 1:50 Tris–EDTA
MUC1 NCL-Muc-1,
Ma695
Novocastra† 1:50 Citrate
MUC2 NCL-Muc-2,
Ccp58
Novocastra† 1:50 Citrate
MUC4 1G8 Zymed‡ 1:50 Citrate
CDX2 CDX-88 BioGenex§ 1:50 Tris–EDTA
Pretreatment was performed by exposing the slides to 0.5%
H2O2 for 10 min, followed by antigen retrieval with Tris–
EDTA pH 9 or citrate pH 6 in a microwave oven: heat to
boiling, then reduced to ‘keep warm’ for 30 min.
HIER, Heat-induced epitope retrieval; CK, Cytokeratin;
EDTA, Ethylenediamine tetraaceticacid.
*DakoCytomation Denmark A ⁄ S, Glostrup, Denmark.
†Novocastra Laboratories Ltd., Newcastle upon Tyne, UK.
‡Zymed Laboratories, Invitrogen Immunodetection, South
San Francisco, CA, USA.
§Biogenex Laboratories Inc., San Ramon, CA, USA.
Pancreatobiliary
CK7
CK20
MUC1
MUC2
MUC4
CDX2
Intestinal
Figure 1. Typical staining for differentiation markers in pancreatic
head adenocarcinomas with pancreatobiliary [left column; positive for
cytokeratin (CK) 7, MUC1 and MUC4] and intestinal (right column;
positive for CK20, MUC2 and CDX2) type of histological differentia-
tion. CK7 and CK20 immunoreactivity is intense and localized to the
cytoplasm.Reactivityfor MUC1 is less intense and localizedboth to the
cytoplasm and ⁄ or the cell membrane, whereas MUC2 reactivity is
localized to the cytoplasm. MUC4 reactivity is predominantly mem-
branous, although some cytoplasmic reactivity is also seen. Only
nuclear CDX2 reactivity is associated with the histological type of
differentiation. In intestinal adenocarcinomas, areas with transition
from negative to positive reactivity in a single tumour gland can often
be seen, as demonstrated here for CK20 and MUC2.
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(categories 0–3) as cut-off points or as a continuous
variable (for CDX2).
statistical analysis
Associations between each immunohistochemical
marker and the histological type were evaluated using
Fisher’s exact test. Interobserver agreement was
estimated using Cohen’s j and categorized as
poor (j < 0.20), fair (0.21 < j < 0.40), moderate
(0.41 < j < 0.60), substantial (0.61 < j < 0.80), or
almost perfect (j > 0.80). Binary logistic regression
with forward variable selection was performed to
identify independent markers of the histological type
of differentiation. Bar graphs showing the combined
expression of each of these independent markers versus
the histological type were examined to identify the
phenotypesthatoptimizedagreementbetweenimmuno-
histochemical and morphological classiﬁcation. Survi-
val data were obtained from the National Registry
of Norway, updated 28 January 2008. Only overall
survival was considered. Follow-up was limited to
5 years. By the end of the study, 79 of 114 patients
were dead; only nine patients were followed for
<5 years (range 3.1–4.8 years). The Kaplan–Meier
method, the log rank test and Cox regression analysis
were used to assess overall survival. For all tests, a
two-sided P < 0.05 was considered to be statistically
signiﬁcant. Statistical analyses were performed using
SPSS 15.0 for Windows software (SPSS Inc., Chicago,
IL, USA).
Results
classification of pancreatic head
adenocarcinomas based on
immunohistochemistry and morphology
Figure 1 shows a typical pattern of immunoreactivity
for the differentiation markers in pancreatic head
adenocarcinomas. As detailed in Table 2, CK7, MUC1
and MUC4 reactivity was more often positive
in pancreatobiliary-type adenocarcinomas, whereas
MUC2, CK20 and CDX2 reactivity was more often
positive in intestinal-type adenocarcinomas (P < 0.05
for each marker). None of these molecules identiﬁed
pancreatobiliary or intestinal-type tumours with sufﬁ-
cient sensitivity and speciﬁcity to yield high predictive
values (Table 2). Interobserver agreement between two
independent reviewers evaluating the histological type
by morphological criteria was almost perfect [j = 0.90;
95% conﬁdence interval (CI) 0.82, 0.99; Figure 2,
red bar], as shown previously.
10 Comparing immuno-
histochemical and morphological classiﬁcation of the
histological type (pancreatobiliary versus intestinal),
agreement was only fair to moderate (j < 0.40 for
each marker; upper 95% CI < 0.60; Figure 2, blue
bars). Evaluation using alternative cut-off values did
not considerably improve agreement (data not shown).
Table 2. Tumour markers in detection of pancreatobiliary versus intestinal histological type of differentiation in pancreatic head
adenocarcinomas
Histological type
Sensitivity,
%
Speciﬁcity,
% P-value*
PPV
(%) 95% CI
Pancreatobiliary Intestinal
Pos Neg Pos Neg
Pancreatobiliary markers
CK7 65 2 33 13 97 28 <0.001 66 [56–75%]
MUC1 32 33 9 37 49 80 0.001 78 [62–89%]
MUC4 23 44 4 42 34 91 0.002 85 [65–95%]
Intestinal markers
CK20 17 48 31 15 67 74 <0.001 65 [49–77%]
MUC2 1 64 6 40 13 98 0.020 86 [42–99%]
CDX2 10 57 25 21 54 85 <0.001 71 [53–85%]
PPV, Positive predictive value (i.e. the probability of obtaining a true positive test result); CI, Conﬁdence interval; Pos,
Immunopositivity; Neg, Immunonegativity (any nuclear reactivity was considered a positive sample for CDX2, whereas
cytoplasmic reactivity in >10% of tumour cells deﬁned a positive sample for the remaining markers); CK, Cytokeratin.
*Fisher’s exact test, P-value for each marker versus the histological type determined morphologically.
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combined expression of two markers (Figure 2, grey
bars), particularly usingthe phenotype CK7+ CDX2) to
identify pancreatobiliary adenocarcinomas (j = 0.48;
95% CI 0.31, 0.65). Binary logistic regression revealed
that CK7+ (P = 0.009), CDX2) (P = 0.002) and
MUC4+ (P = 0.026) were independent markers of the
pancreatobiliary type. Bar graphs showing these three
markers versus morphological histological type were
thereforeexaminedtoobtaintheoptimalcombinationof
differentiation markers (Figure S1) to classify tumours
aseitherimmunohistochemicallypancreatobiliary(‘IHC
pancreatobiliary’) or immunohistochemically intes-
tinal (‘IHC intestinal’). The phenotypes CK7+ MUC4+
and CK7+ CDX2) optimally classiﬁed tumours as
IHC pancreatobiliary, and the phenotypes CK7) and
MUC4) CDX2+ optimally classiﬁed tumours as IHC
intestinal (Figure 3). The positive predictive value for
identiﬁcation of pancreatobiliary versus intestinal
histological type was 78% (95% CI 67, 87); sensitivity
87% (95% CI 76, 93), speciﬁcity 65% (95% CI 50, 78).
However, even with these optimized combinations, the
j-valueforimmunohistochemicalversusmorphological
classiﬁcation was only moderate (0.53; 95% CI 0.37,
0.69; Figure 2, green bar).
survival analysis
On univariate analysis of all pancreatic head adeno-
carcinomas (Figure 4), expression of the pancreato-
biliary type markers CK7, MUC1 and MUC4 predicted a
poor prognosis, whereas expression of the intestinal
marker CDX2 was signiﬁcantly associated with better
survival (Figure 4A–D, P < 0.05 for each marker).
Combining markers for the optimal immunohisto-
chemical classiﬁcation of the histological type, IHC
pancreatobiliary type signiﬁcantly predicted poor sur-
vival compared with IHC intestinal type (Figure 4E,
P = 0.001). Survival for pancreatobiliary versus intes-
tinal type based on morphological evaluation is shown
in Figure 4F (P < 0.001).
In morphologically determined pancreatobiliary-
type adenocarcinomas (n = 67), most tumours (58
of 65) had diffuse CK7 expression (in >40% of the
tumour cells) or were largely negative for MUC2 (62 of
65) and CDX2 (57 of 65). These markers were not
analysed further. CK20, MUC1 and MUC4 were
variably expressed in pancreatobiliary adenocarcin-
omas (Table 3). Whereas CK20 was non-signiﬁcant,
Figure 3. Algorithm for classiﬁcation of pancreatobiliary versus
intestinal type using immunohistochemical markers independently
associated with histological type. Optimized immunohistochemical
classiﬁcation (IHC) corresponds to morphological classiﬁcation in 88
of 113 tumours (78%); i.e. 58 pancreatobiliary tumours and 30
intestinal tumours were correctly identiﬁed by immunohistochemical
evaluation [positive predictive value for identiﬁcation of pancreato-
biliary versus intestinal histological type was thus 78%, 95%
conﬁdence interval (CI) 67, 87; sensitivity was 87%, 95% CI 76, 93,
and speciﬁcity was 65%, 95% CI 50, 78].
Figure 2. Comparison of histological and immunohistochemical
classiﬁcation of pancreatic head adenocarcinomas using j statistics
(with 95% conﬁdence intervals). Red bar represents interobserver
agreement between two independent reviewers of the histological
type (reported previously
10). The other bars compare histological
classiﬁcation (pancreatobiliary versus intestinal) with immunohisto-
chemical classiﬁcation (IHC pancreatobiliary versus IHC intestinal;
single markers, blue bars; marker combinations, grey bars; the
optimized marker combination, green bar).
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P = 0.038) and MUC4 expression in any tumour cell
(Figure 5B, P = 0.029) each signiﬁcantly predicted a
poor prognosis. Combining MUC1 and ⁄ or MUC4
expression at these levels (MUC1 > 40% and ⁄ or
MUC4 > 0%, versus MUC1 < 40% and MUC4 = 0%)
indicated a clear survival disadvantage for patients
with pancreatobiliary differentiated adenocarcinomas
Figure 4. Overall survival after pancreaticoduodenectomy predicted by markers associated with histological type and by histology alone.
A, Cytokeratin (CK) 7+ (n = 94) versus CK7) (n = 15); P = 0.029. B, MUC1+ (n = 39) versus MUC1) (n = 68); P = 0.008. C, MUC4+
(n = 25) versus MUC4) (n = 84); P = 0.041. D, CDX2) (n = 78) versus CDX2+ (n = 31); P = 0.019. E, IHC pancreatobiliary type
(CK7+ MUC4+ or CK7+ CDX2), n = 72) versus IHC intestinal type (CK7) or MUC4) CDX2+, n = 37); P = 0.001. F, Histological type (updated
from
10), pancreatobiliary (n = 65) versus intestinal (n = 45); P < 0.001.
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these markers at these levels was signiﬁcantly associ-
ated with pancreatic versus non-pancreatic tumour
origin (P = 0.001), while not associated with lymph
node or resection margin involvement, vascular
or perineural inﬁltration, degree of differentiation,
tumour size or pT stage (data not shown). Starting
with all these factors in a multivariable Cox regression
analysis, with backward stepwise selection of covari-
ates having the lowest P-values, MUC1 > 40% and ⁄ or
MUC4 > 0% expression independently predicted a
poor prognosis (P = 0.043; hazard ratio 2.02, 95%
CI 1.02, 3.98), adjusting for nodal involvement, vessel
involvement and tumour size (Table 4).
Table 3. Unadjusted Cox regression analysis in pancreato-
biliary differentiated adenocarcinomas
Positive tumour
cells (%) N
Hazard
ratio 95% CI
CK20
0 (ref) 27 1.00 –
0–10 22 1.09 0.59, 2.03
10–40 7 1.43 0.58, 3.55
>40 7 0.93 0.40, 2.18
MUC1
0 (ref) 6 1.00 –
0–10 27 1.45 0.50, 4.22
10–40 12 2.13 0.67, 6.71
>40 18 2.82 0.94, 8.49
MUC4
0 (ref) 21 1.00 –
0–10 23 1.96 1.01, 3.81
10–40 17 1.80 0.87, 3.75
>40 4 N ⁄ A–
Hazard ratio >1 indicates increased risk of death compared
with ref.
Ref, reference group; N ⁄ A, not applicable (due to small
numbers); CK, cytokeratin.
Figure 5. Overall survival after pancreaticoduodenectomy for
pancreatobiliary differentiated adenocarcinomas. A, MUC1 expres-
sion in >40% of tumour cells (n = 18) versus <40% or no MUC1
expression (n = 45); P = 0.038. B, Any MUC4 expression (n = 44)
versus no MUC4 expression (n = 21); P = 0.029. C, MUC1 >40%
and ⁄ or MUC4 >0%, yes (n = 47) versus no (n = 17); P = 0.009.
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carcinomas (n = 47), none of the differentiation
markers CK7 (P = 0.62), CK20 (P = 0.85), MUC1
(P = 0.90), MUC2 (P = 0.43), MUC4 (P = 0.94) or
CDX2 (P = 0.86) was signiﬁcantly associated with
survival.
Discussion
Determination of the histological type based on the
predominant pattern of histological differentiation
5 may
be performed with almost perfect interobserver agree-
ment and could be a useful adjunct to classiﬁcation of
pancreatic head adenocarcinomas based on standard
histopathological examination.
10 The present study has
demonstrated that classiﬁcation of pancreatic head
adenocarcinomas using common immunohistochem-
ical markers associated with pancreatobiliary versus
intestinal histological type is only in moderate
agreement with classiﬁcation based on morpho-
logical criteria. These markers may, however, pro-
vide prognostic information beyond indicating the
histological type. Among patients with morphologi-
cally determined pancreatobiliary adenocarcinomas,
immunohistochemical detection of MUC1 and MUC4
identiﬁes a subgroup of patients with a particularly
poor prognosis.
The three anatomical structures that may give rise to
pancreatobiliary-type adenocarcinomas in the pancre-
atic head, i.e. the pancreas, ampulla and distal bile
duct, are embryologically derived from the endodermal
lining of the duodenum, as are periampullary tumours
of intestinal differentiation. As they have a common
tissue origin, it is not surprising that pancreatobiliary-
type and intestinal-type adenocarcinomas may have
overlapping expression of cellular markers, although
differential expression of these markers in pancreato-
biliary and intestinal-type tumours has frequently
been reported.
6,8,17,18,22–25,39 Determination of the
histological type of differentiation in pancreatic head
adenocarcinomas is important for a number of reasons.
We have previously suggested that the histological type
might provide more precise information regarding
long-term survival than the anatomical site of tumour
origin.
10 Failure to exclude prognostically favourable
types of adenocarcinomas, e.g. intestinal ampullary
adenocarcinomas, may obscure survival predictions
in studies of resected pancreatic head adenocarcin-
omas.
2,40 A potentially important clinical implication
of this is that selection of patients for chemo-
therapy and study protocols might be based on the
tumour’s type of differentiation as well as tumour
origin. As we
10 and others
6–9 have demonstrated, even
ductal adenocarcinomas arising from the pancreas or
distal bile duct may have intestinal histological type of
differentiation.
To our knowledge, this is the ﬁrst report of differenti-
ation marker expression in a collective series of pancre-
atic head adenocarcinomas including all four subtypes
with respect to anatomical origin. Previous investiga-
tors, although often not including all four subtypes in
the analysis, have in general found that expression
of CK7, MUC1 and MUC4 predominantly identiﬁes
tumours with pancreatobiliary differentiation and a
poor prognosis, whereas expression of CK20, MUC2 and
CDX2 predominantly identiﬁes tumours with intestinal
differentiation and a good prognosis.
6,8,17,18,21–25,39 No
particular combination of biomarkers has been esta-
blished for the immunohistochemical classiﬁcation of
histological type. In the present study, we obtained
at best moderate to substantial agreement with
morphological classiﬁcation even when using the
marker combination optimally corresponding to the
histological type. We deﬁned the cut-off values for
immunohistochemical classiﬁcation prior to statistical
analysis,
41,42 as required if such markers are to be
used in clinical practice or clinical studies. In previous
studies, cut-off values discriminating between negative
and positive samples have varied considerably, in the
range 0–5%
6,22,26,32,43 to 20–25%.
19,21,25 Alternative
Table 4. Adjusted Cox
regression analysis in
pancreatobiliary differenti-
ated adenocarcinomas
Hazard ratio 95% CI P-value
MUC1 > 40%
and ⁄ or MUC4 > 0%
Yes (versus no) 2.02 1.02, 3.98 0.043
Lymph node
involvement
Yes (versus no) 3.53 1.72, 7.21 <0.001
Vessel involvement Yes (versus no) 1.93 1.04, 3.59 0.037
Tumour size >25 mm
(versus £25 mm)
2.54 1.39, 4.63 0.002
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between pancreatobiliary and intestinal differentiation
in the present study.
44 However, further markers
associated with the histological type of differentiation
should be evaluated, and several cut-off values
discriminating between poor and good prognostic
groups should be explored for these markers. Other
antibodies directed against the mucins MUC1, MUC2
and MUC4 should also be evaluated, since these
proteins are heavily glycosylated, and altered glyco-
sylation in cancer may inﬂuence the reactivity to such
antibodies.
45,46
Tissue microarrays could introduce selection bias of
the histological type, particularly since differentiation
markers are not always homogeneously expressed
within a single tumour. However, only 10 tumours
with both types of differentiation were identiﬁed in the
study group consisting of 114 consecutive resections,
and for each of these tumours with mixed-type
histology, either pancreatobiliary or intestinal differen-
tiation was readily identiﬁed as the predominant
pattern. This was reﬂected in the high interobserver
agreement in morphological classiﬁcation of the
histological type.
In the present study, MUC1 and MUC4 expression
identiﬁed a subgroup of patients that had a particularly
poor prognosis among patients with a differentiated
pancreatobility tumour. Both MUC1 and MUC4 are
membrane-associated mucins involved in cellular
contact and signalling and may play a role in the
autonomous and dysregulated proliferation seen in
cancer cells.
47 These mucin proteins are not necessarily
expressed simultaneously,
21 and the combined evalu-
ation of MUC1 and MUC4 expression might therefore
increase sensitivity in detection of prognostically poor
tumours among these patients. The subgroup analysis
examining the prognostic impact of MUC1 and MUC4
expression included 65 patients. Although this number
is relatively small, most of these patients (n = 55) were
dead by the end of the study, and only two of the eight
censored patients in this subgroup were followed for
<5 years (these were followed for 4.2 and 4.8 years,
respectively). Actual 5-year survival was thus almost
complete, and the high number of events during the
study period made the subgroup analysis feasible.
The results of this analysis were conﬁrmed by Cox
regression analysis adjusting for possible confounders,
demonstrating that MUC1 and ⁄ or MUC4 expression
was indeed an independent prognostic factor among
patients with pancreatobiliary differentiated adeno-
carcinomas.
In conclusion, morphological classiﬁcation of histo-
logical type signiﬁcantly discriminates between prog-
nostically poor pancreatobiliary and prognostically
good intestinal types of pancreatic head adenocarcin-
omas. Agreement between immunohistochemical and
morphological classiﬁcation of pancreatic head adeno-
carcinomas is only moderate, and immunohisto-
chemical characterization is thus not appropriate to
discriminate between these two histological types.
However, MUC1 and MUC4 expression may identify
patients with a particularly poor prognosis among
morphologically determined pancreatobiliary-type pan-
creatic head adenocarcinomas.
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Figure S1. Bar graph demonstrating that the pheno-
types CK7
+ MUC4
+ (CDX2
+ ⁄ )) and CK7
+ CDX2
)
(MUC4
+ ⁄ )) were predominantly pancreatobiliary
(‘IHC pancreatobiliary’), while the remaining pheno-
types, CK7
+ (MUC4
+ ⁄ ) CDX2
+ ⁄ )) and MUC4
) CDX2
+
(CK7
+ ⁄ )) were predominantly intestinal (‘IHC intes-
tinal’).
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